Delcath Systems (NASDAQ:DCTH) Receives Buy Rating from HC Wainwright

Delcath Systems (NASDAQ:DCTH)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $22.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 73.09% from the stock’s current price.

Other analysts also recently issued reports about the stock. Stephens reissued a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.50.

Delcath Systems Stock Performance

Shares of DCTH opened at $12.71 on Tuesday. Delcath Systems has a fifty-two week low of $3.70 and a fifty-two week high of $13.30. The firm has a market cap of $406.39 million, a price-to-earnings ratio of -9.41 and a beta of 0.87. The firm has a 50 day moving average price of $11.33 and a 200-day moving average price of $9.83.

Institutional Trading of Delcath Systems

Large investors have recently modified their holdings of the business. Polar Asset Management Partners Inc. purchased a new position in shares of Delcath Systems during the third quarter valued at approximately $1,594,000. Shellback Capital LP purchased a new stake in Delcath Systems in the second quarter worth $1,353,000. Principal Financial Group Inc. purchased a new position in Delcath Systems during the 3rd quarter valued at about $808,000. Renaissance Technologies LLC purchased a new stake in shares of Delcath Systems in the 2nd quarter worth approximately $694,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Delcath Systems in the 2nd quarter worth about $370,000. 61.12% of the stock is owned by institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.